| Id: | acc4180 |
| Group: | 1sens |
| Protein: | Smad2 |
| Gene Symbol: | Smad2 |
| Protein Id: | Q62432 |
| Protein Name: | SMAD2_MOUSE |
| PTM: | phosphorylation |
| Site: | unclear |
| Site Sequence: | |
| Disease Category: | Cardiovascular and circulatory system diseases |
| Disease: | Cardiac Fibrosis |
| Disease Subtype: | |
| Disease Cellline: | |
| Disease Info: | |
| Drug: | serelaxin + enalapril |
| Drug Info: | Serelaxin is a drug used for certain medical conditions | Enalapril is commonly prescribed for treating hypertension and heart failure. |
| Effect: | modulate |
| Effect Info: | "The combined effect of serelaxin and enalapril inhibits the phosphorylation of Smad2 to a greater extent, reducing cardiac fibrosis by at least 2-fold." |
| Note: | drug comb |
| Score: | 4.0 |
| Pubmed(PMID): | 24866131 |
| Sentence Index: | 24866131_6 |
| Sentence: | "Additionally, the combined effects of serelaxin and enalapril reduced cardiac fibrosis by at least 2-fold compared with enalapril alone, when administered preventatively or therapeutically; by suppressing transforming growth factor-beta1 expression and phosphorylation of Smad2 (an intracellular regulator of transforming growth factor-beta1 activity; both P<0.05 versus enalapril alone) to a greater extent." |
Sequence & Structure:
MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTANTVDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMD| Residue | Position | State | Disease | Class | PMID |
|---|---|---|---|---|---|
| - | - | D | Chronic kidney disease | Phosphorylation | 23264657 |
State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.
